A new Beginning..., page-3089

I agree @MSIMaker - I believe the focus will initially be on Telehealth deals in Europe and Australia initially, in parallel with the pilot study in the German hospital network.

The study will allow us to quantify the benefits (financial, patient flow) of using ResAppDx in a clinical setting and identify any unforeseen issues in its implementation. Clinical working groups will need to review and sign off changes to workflows and procedures before ResAppDx is implemented and this is a multi month process.

Quantifying the financial and patient flow benefits will enable us to better understand the value proposition of ResAppDx and price is accordingly. It is common in hospitals for software to be licensed on a per bed basis, rather than per use, so I wouldn’t be surprised if the pricing model goes down this path.